Sign in
Taking people in United StatesNo phase

Noninvasive focused ultrasound of the brain for fibromyalgia pain

Tests focused ultrasound aimed at the brain to ease pain in fibromyalgia.

Key facts

Who runs it
SPIRE Therapeutics Inc.
Where
Ann Arbor, Manhasset, Minneapolis, Morgantown, New York, Philadelphia, Salt Lake City, and St Louis, United StatesSee the 8 sites
Trial code
Registry title
Ultrasonic Neuromodulation of Cingulate Cortex for Fibromyalgia
Status
Recruiting
People taking part
180 people, planned
Started
11 Dec 2025
Expected to end
Dec 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Focused Ultrasound
Record updated
20 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with fibromyalgia whose pain has not improved with medicines and with physical therapy or CBT (talking therapy). It tests a gentle ultrasound brain stimulation against a fake (sham) treatment.

Age
22 years or older
Sex
All sexes
Disease stage
Fibromyalgia by the 2016 American College of Rheumatology criteria. Pain in at least 4 of 5 body regions, symptoms for at least 3 months. Pain score of 4 or more on the NRS-11 pain scale at screening and at baseline (averaged over 3 days).
Earlier treatment
At least two fibromyalgia medicines did not help, and at least 1 of them FDA-approved for fibromyalgia (e.g., pregabalin, duloxetine, milnacipran). At least one try of physical therapy or CBT did not help. Same psychiatric treatment for at least 1 month before screening. No electroconvulsive therapy, transcranial magnetic stimulation, ketamine or esketamine in the past 30 days.

Main reasons for not taking part

  • Bipolar disorder, schizophrenia-spectrum disorder, or moderate-high suicide risk
  • Moderate or severe alcohol or drug use disorder in the past 6 months
  • Progressive nerve disease, cancer-related pain, or autoimmune conditions known to cause pain
  • Pregnant or breastfeeding
  • Cannot have an MRI, or has implants like pacemakers or neurostimulators

The registry criteria, word for word

Show all 32 criteriaShow less

Who can take part

  • Willing and able to provide informed consent
  • Age ≥ 22 years
  • Meets 2016 American College of Rheumatology criteria for fibromyalgia:; Generalized pain, defined as pain in at least 4 of 5 regions, is present, AND; Widespread pain index (WPI) ≥ 7 and symptom severity scale score (SSS) ≥ 5, or WPI of 4-6 and SSS score ≥ 9, AND; Symptoms have been present at a similar level for at least 3 months, AND; A diagnosis of fibromyalgia is valid irrespective of other diagnoses. A diagnosis of fibromyalgia does not exclude the presence of other clinically important illnesses
  • Failure of at least two evidence-based medications or medications that are commonly used in clinical practice to treat fibromyalgia (e.g., pregabalin, duloxetine, milnacipran, sublingual cyclobenzaprine hydrochloride, tricyclics (e.g., amitriptyline, nortriptyline, desipramine),gabapentin, gabapentinoids, NSAIDS (including Cox-2 inhibitors), acetaminophen, SSRIs, SSNIs, muscle relaxants, non-sublingual forms of cyclobenzaprine hydrochloride, opioids, benzodiazepines), at least 1 of which is FDA-approved for the treatment of fibromyalgia (e.g., pregabalin, duloxetine, milnacipran, and sublingual cyclobenzaprine hydrochloride)
  • Failure of one or more attempts at physical or Cognitive Behavioral Therapy (CBT) including:; Aerobic exercise like walking, cycling, and swimming,; Water therapy/hydrotherapy with warm water exercises,; Tai Chi involving slow, controlled movements,; Yoga,; Resistance training,; Bodyweight exercises,; Pilates,; Myofascial release therapy applying gentle pressure on trigger points,; Massage therapy,; Trigger point therapy targeting specific pain points,; Joint mobilization,; Postural retraining to correct body alignment,; Balance and coordination exercises,; Feldenkrais method for movement awareness,; Alexander technique to enhance posture and movement efficiency,; Transcutaneous Electrical Nerve Stimulation (TENS) for pain relief,; Heat therapy using hot packs, infrared, or paraffin wax,; Cold therapy with ice packs or cryotherapy,; Ultrasound therapy for deep tissue relaxation,; Biofeedback to control muscle tension and pain response,; Gentle static stretching for prolonged duration,; Active dynamic stretching for full range of motion,; Proprioceptive Neuromuscular Facilitation (PNF) stretching,; Hydrotherapy pool exercises,; Ai Chi (water-based Tai Chi),; Underwater treadmill therapy, aa) Graded motor imagery (GMI), bb) Mirror therapy to retrain brain-body connections, cc) Mindfulness-based stress reduction (MBSR) combining meditation and movement, dd) Balance exercises to improve stability, ee)Gaze stabilization techniques for dizziness and disorientation, ff) CBT
  • Pain score of ≥ 4 on Numerical Rating Scale (NRS-11) at Screening visit
  • Pain score of ≥ 4 on NRS-11 at Baseline visit averaged over 3 consecutive calendar days
  • Stated willingness and ability to comply with all study procedures
  • Has remained on the same psychiatric treatment regimen (e.g., medication, psychotherapy) for at least one (1) month prior to screening, and has stated willingness to remain on the same regimen for the duration of the study unless a change in treatment is recommended or agreed upon by the site investigator
  • For participants who could potentially become pregnant: negative urine pregnancy test at screening; agreement to either abstain from heterosexual intercourse or use an acceptable contraceptive method during study participation. Acceptable contraceptive methods include hormonal contraception, including oral contraceptive pills, tubal ligation, vasectomized partner, IUD or IUS (intrauterine device or system), or long-acting reversible contraceptives (LARC)

Who cannot take part

  • Any previous diagnosis of bipolar disorder or schizophrenia-spectrum disorder during the participant's lifetime, according to Diagnostic and Statistical Manual of Mental Disorders, version 5 (DSM-5-TR) criteria
  • Treatment with electroconvulsive therapy, transcranial magnetic stimulation, ketamine, or esketamine in the past 30 days
  • MRI contraindication or electrically sensitive implants such as pacemakers, implanted cardioverter defibrillators, or neurostimulators. Routine dental hardware is not exclusionary
  • Previously enrolled in a DIADEM clinical trial. Note: a patient who screen fails is able to be rescreened at most one time
  • New or existing diagnosis of moderate or severe alcohol or other substance use disorder in the past 6 months, according to DSM-5-TR criteria
  • New or existing diagnosis of obsessive-compulsive disorder and/or posttraumatic stress disorder in the past 30 days, according to DSM-5-TR criteria, and which is unstable in the clinical judgment of the investigator
  • New or existing primary diagnosis of anorexia nervosa, bulimia nervosa, or binge eating disorder in the past 3 months, according to DSM-5-TR criteria
  • Clinically significant neurodevelopmental, neurocognitive, or personality disorder, according to DSM-5-TR criteria
  • Lifetime history of a serious suicide attempt in the medical opinion of the site investigator
  • Currently diagnosed progressive neurological disease such as multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, rapid progressive arachnoiditis, brain or spinal cord tumor, or severe/critical spinal stenosis (stenosis)
  • Cancer-related pain
  • Diagnosis of malignancy other than basal cell carcinoma, or carcinoma in situ of the cervix within the past five years, to include life expectancy less than one year due to advanced malignancy
  • Autoimmune conditions that are known to cause pain
  • Inadequately managed general medical condition, in the opinion of the site investigator
  • Lifetime history of cerebral small vessel disease
  • Lifetime history of intracranial hemorrhage
  • Has a history of a medical or psychiatric disorder, disease, condition, injury, symptoms, or circumstance that, in the opinion of the site investigator, may (1) reduce the participant's ability to fulfill the study requirements as per protocol; (2) adversely impact the integrity of the data or the validity of the study results; or (3) pose an increased risk to the participant during study participation
  • Moderate-High Risk of Suicide, according to the Columbia-Suicide Severity Rating Scale (C-SSRS) Screen Version - Recent (i.e., answers YES to Question 3 and NO to Question 6 (Moderate Risk), or YES to Question 4, 5, or 6 (High Risk)), or in the clinical judgement of the site investigator
  • Changes in prescribed treatments for pain in the past 2 months that could confound study outcome assessments, in the opinion of the site investigator
  • Pregnant or breast feeding
  • MRI intolerance
  • Participants with braids, dreadlocks, or other hairstyles that prevent access to the side of the head and who are unwilling to temporarily adjust their hairstyle to allow such access

Where in United States

  • University of MichiganAnn Arbor, United StatesContact: Katherine Scott, RN, BSNTaking people
  • Northwell Health - The Feinstein Institutes of Clinical ResearchManhasset, United StatesContact: Clinical Research TeamTaking people
  • University of Minnesota Medical Center, FairviewMinneapolis, United StatesContact: Eric WilliamsonTaking people
  • WVU Rockefeller Neuroscience InstituteMorgantown, United StatesContact: Tami Deal, CCRCTaking people
  • Icahn School of Medicine at Mount SinaiNew York, United StatesContact: Maya CampbellTaking people
  • University of PennsylvaniaPhiladelphia, United StatesContact: Sean McKenzieTaking people
  • University of UtahSalt Lake City, United StatesContact: Rachel Douglas, BS, CCRCTaking people
  • Washington University in St. LouisSt Louis, United StatesContact: Cristina Bowman, RNTaking people

About the trial

What the trial wants to find out

The goal of this clinical trial is to evaluate a new noninvasive brain stimulation intervention for fibromyalgia and to determine its effectiveness in reducing pain. Participants will receive four treatments over the course of one month and will complete surveys at multiple time points throughout the 16-week study.

The 2 groups in the trial

  • Focused UltrasoundExisting treatment, for comparison
  • Sham UltrasoundSham treatment, for comparison

    Treatment: Focused Ultrasound

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Ultrasonic Neuromodulation of Cingulate Cortex for Fibromyalgia: A Blinded Randomized Sham-Controlled Trial
Plain-language title
Noninvasive focused ultrasound of the brain for fibromyalgia painGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
20 August 2026